NCT07045532 Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI
| NCT ID | NCT07045532 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | COPD |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-09-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
A Clinical Study Based on Magnetic Resonance Imaging of the Lungs to Assess the Efficacy of Thermal Vapor Ablation and Pulmonary Nodule Ablation in Chronic Obstructive Pulmonary Disease After Surgery. The efficacy of hot steam ablation for chronic obstructive pulmonary disease was evaluated using the innovative MRI sequence PREFUL\_MRI, and the efficacy of pulmonary nodule ablation was evaluated using the innovative MRI sequence GRASP\_MRI.
Eligibility Criteria
Inclusion Criteria: 1. Age \>18 years old; 2. Patients with pulmonary nodules: patients with pulmonary nodules indicated by chest CT, pathologically diagnosed as malignant, and receiving ablative treatment, including transthoracic and percutaneous ablative methods, including radiofrequency, microwave, and freezing; 3. COPD patients: patients diagnosed with COPD according to the GOLD principle and treated with thermal steam ablation for COPD; 4. Understand the study and sign the informed consent. Exclusion Criteria: 1. Chest CT nodules in patients with pulmonary nodules were pure ground glass nodules; 2. Patients who install or carry metal implants such as cardiac pacemakers, heart stents, artificial heart valves in the body or suffer from claustrophobia, allergy to contrast media and other reasons are not suitable for MRI examination; 3. severe cardiopulmonary dysfunction and other diseases that may significantly increase the risk of ablation surgery; 4. Patients with severe COPD exace
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.